


Cabazitaxel

ALTERNATE NAME: RPR116258A
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate.
XRP6258
TXD-258

CATALOG #: B2399-5 5 mg
B2399-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₄₅H₅₇NO₁₄

MOLECULAR WEIGHT: 835.93

CAS NUMBER: 183133-96-2

APPEARANCE: White solid

PURITY: ≥98% by HPLC

SOLUBILITY: >5 mg/ml DMSO

DESCRIPTION: Cabazitaxel is a second generation semisynthetic taxane derived from 10-deacetylbaccatin with potent anticancer activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Cabazitaxel is more potent than docetaxel (Cat. No. 2232) in P-glycoprotein-expressing cell lines with in vitro acquired resistance to taxanes or other chemotherapeutic agents.

REFERENCES: Vrignaud, P., et al. (2013). Cancer Res. 19, 2973-2983.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

Docetaxel (2232)
Epothilone B (2012)
Paclitaxel (1567)

DISCLAIMER: *FOR RESEARCH USE ONLY! Not to be used on humans.*